Multiinstitutional prospective interventional study of biomarkers to predict efficacy and prognosis after nivolumab in patients with previously treated advanced renal cell carcinoma - URivO

akano Yuzo0 个研究点目标入组 141 人开始时间: 2019年3月7日最近更新: 2024年4月1日

适应症

试验速览

The study was discontinued because it was judged inappropriate to continue the study due to inappropriate cases in the study.

•Advanced renal cell carcinoma with unresectable or metastatic history who had been treated with tyrosine kinase inhibitors
•Patients who have at least one tumorous lesion of 10 mm over in CT/ MRI and evaluated with RECIST ver1.1
•Nuetrphils >= 1500 cells/mm3, platelets >= 75000 cells/mm3, hemoglobin >= 9.0 g/dl, AST <= 78IU/l, ALT <= 85IU/l, total bilirubin <= 1.5 mg/dl, serum creatinine <= 2.0 mg/dl
•Over 20 years old patients
•written informed consent

•Patients who have been administered immune checkpoint inhibitors including nivolumab in the past
•Patients with active infection of bacteria, fungi or viruses
•Patients who have a history of malignant tumors other than renal cell carcinoma and are judged not to be cured
•Patients suffering from other severe acute or chronic diseases
•Pregnant women or women who may be pregnant or lactating women
•Patients complicated with psychiatric disorders or psychiatric symptoms and judged to be difficult to participate in the study
•Patients found to be unacceptable to components of test drugs (or excipients)
•For other reasons, patients who judged ineligible for participation in this study by physician

发起方

akano Yuzo